Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document

NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science

NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing

Cancer Policy

AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG

HHS ordered to cut 35% of spending on contracts

National Cancer Registrars Association launches campaign to protect U.S. cancer registries

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

HHS said it would terminate Women’s Health Initiative, then reconsidered

DOJ letters to peer-reviewed journals allege partisan bias in medical literature

Clinical Roundup

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

UC Lung Cancer Consortium and AstraZeneca partner to improve early lung cancer detection

In The Clinic

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Latest Issue

NEWS ALERTS

Stay up to date on the latest news in oncology by joining our mailing list.

UPCOMING EVENTS

May 2025

Conversations with The Cancer Letter

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Contributors

Betty Ferrell, PhD, MSN, CHPN

W. Kimryn Rathmell, MD, PhD, MMHC

Suresh S. Ramalingam, MD

Mustafa Raoof, MD

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Kelly Spill opted for dostarlimab trial, avoiding rectal cancer treatment that would leave her infertile
Six years later, she is well—and pregnant with her third child

The White House “skinny budget” document cuts NIH by nearly 40%
The cuts are consistent with the previously leaked “passback” document

NIH eliminates the NCI Board of Scientific Advisors
Over its 28 year history, BSA shaped NCI-funded extramural science

NIH cuts threaten U.S. edge in biomedical research: “We are giving China the opportunity of a lifetime”
Cancer research also took center stage at Senate appropriations hearing

AACI letter to NIH’s Bhattacharya opposes centralizing review of CCSG

HHS ordered to cut 35% of spending on contracts

National Cancer Registrars Association launches campaign to protect U.S. cancer registries

White House preliminary budget document provides no funds for highly impactful CDC cancer registries program

HHS said it would terminate Women’s Health Initiative, then reconsidered

DOJ letters to peer-reviewed journals allege partisan bias in medical literature

Sotorasib + panitumumab offers better outcomes in colorectal cancer that no longer responds to treatment

Sasanlimab combination significantly improves EFS in BCG-naïve, high-risk non-muscle invasive bladder cancer

Pembro + standard-of-care improves survival in locally advanced head-and-neck cancer

TAR-200 monotherapy demonstrates highest complete response rate with sustained clinical benefits in certain bladder cancers

Zongertinib demonstrates clinical benefit in advanced HER2-mutated lung cancer

UC Lung Cancer Consortium and AstraZeneca partner to improve early lung cancer detection

TIL + pembro regimen achieves 24% response rate in solid epithelial tumors, marking a step forward in immunotherapy research

Only half of adolescents and young adults with cancer get fertility counseling before treatment
Oncofertility consult is an oft-overlooked standard of care

Survey reveals most Americans are uninformed about HPV
A vaccine can prevent cancer—most people don’t take it

The new therapeutic imperative in cancer management: Sequence, biosimulate, treat

LLS former CSO: Immunotherapy, precision medicine redefined blood cancer treatment

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Betty Ferrell, PhD, MSN, CHPN

W. Kimryn Rathmell, MD, PhD, MMHC

Suresh S. Ramalingam, MD

Mustafa Raoof, MD

Never miss an issue!

Login

Neoadjuvant dostarlimab averts brutal surgery in 80% of patients with dMMR solid tumors

Steven Libutti tells us about building a $900 million cancer hospital for Rutgers RWJBarnabas Health

Karen Knudsen tells us why she took the CEO job at the Parker Institute for Cancer Immunotherapy

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising recordCurrent record: $507,000. Proceeds to go to LLS as NIH funding is slashed

Jonathan Friedberg tells us how he built a cancer center in an underserved area of New York State

Never miss an issue!

Login

Brian Druker, developer of Gleevec, eyes a new feat: Setting the Boston Marathon fundraising record
Current record: $507,000. Proceeds to go to LLS as NIH funding is slashed